Cell 82 , 32843298.e3287 (2022)
First-line therapies, including metformin, sodium-glucose cotransporter-2 inhibitors (SGLT-2i), and Glucagon-like peptide-1 (GLP-1) receptor agonists, are selected according to patient-specific risk factors
They endure a daily burden of pain, fatigue, and swelling, as well as gait abnormalities and leg joint issues (Priglinger et al., 2017
Symptoms of DPN vary according to the class of involved sensory fibers, presenting with pain and unpleasant sensations if small fibers are involved and with numbness and loss of protective sensation (LOPS) if large fibers are involved
KRAVITZ Does saving three or four visits also reduce treatment time
The evaluation framework for specific diets [A: 33:30, V: 37:00]